1. Home
  2. AEMD vs BDRX Comparison

AEMD vs BDRX Comparison

Compare AEMD & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

HOLD

Current Price

$0.68

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Logo Biodexa Pharmaceuticals plc

BDRX

Biodexa Pharmaceuticals plc

HOLD

Current Price

$2.20

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEMD
BDRX
Founded
1984
2000
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
2.2M
IPO Year
2008
2015

Fundamental Metrics

Financial Performance
Metric
AEMD
BDRX
Price
$0.68
$2.20
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
196.1K
44.9K
Earning Date
02-12-2026
09-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$0.60
52 Week High
$5.89
$11.88

Technical Indicators

Market Signals
Indicator
AEMD
BDRX
Relative Strength Index (RSI) 24.92 32.23
Support Level $0.64 $1.04
Resistance Level $0.83 $3.68
Average True Range (ATR) 0.12 0.26
MACD 0.01 -0.05
Stochastic Oscillator 6.47 9.62

Price Performance

Historical Comparison
AEMD
BDRX

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

About BDRX Biodexa Pharmaceuticals plc

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Share on Social Networks: